AU2018284249B2 - Aminothiazole compounds as protein kinase inhibitors - Google Patents

Aminothiazole compounds as protein kinase inhibitors Download PDF

Info

Publication number
AU2018284249B2
AU2018284249B2 AU2018284249A AU2018284249A AU2018284249B2 AU 2018284249 B2 AU2018284249 B2 AU 2018284249B2 AU 2018284249 A AU2018284249 A AU 2018284249A AU 2018284249 A AU2018284249 A AU 2018284249A AU 2018284249 B2 AU2018284249 B2 AU 2018284249B2
Authority
AU
Australia
Prior art keywords
cancer
compound
salt
alkyl
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018284249A
Other languages
English (en)
Other versions
AU2018284249A1 (en
Inventor
Weir-Torn Jiaang
Chuan Shih
Hui-Jen TSAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of AU2018284249A1 publication Critical patent/AU2018284249A1/en
Application granted granted Critical
Publication of AU2018284249B2 publication Critical patent/AU2018284249B2/en
Assigned to NATIONAL HEALTH RESEARCH INSTITUTES reassignment NATIONAL HEALTH RESEARCH INSTITUTES Request for Assignment Assignors: NATIONAL HEALTH RESEARCH INSTITUTES, SHIH, CHUAN
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018284249A 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors Active AU2018284249B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518855P 2017-06-13 2017-06-13
US62/518,855 2017-06-13
PCT/US2018/037221 WO2018231910A1 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2018284249A1 AU2018284249A1 (en) 2019-12-12
AU2018284249B2 true AU2018284249B2 (en) 2021-06-24

Family

ID=64562741

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018284249A Active AU2018284249B2 (en) 2017-06-13 2018-06-13 Aminothiazole compounds as protein kinase inhibitors

Country Status (13)

Country Link
US (1) US10300061B2 (enExample)
EP (1) EP3638237B1 (enExample)
JP (1) JP6979595B2 (enExample)
KR (1) KR102372288B1 (enExample)
CN (1) CN110831596B (enExample)
AU (1) AU2018284249B2 (enExample)
CA (1) CA3064081C (enExample)
ES (1) ES2949616T3 (enExample)
MX (1) MX393992B (enExample)
MY (1) MY201291A (enExample)
TW (1) TWI667236B (enExample)
WO (1) WO2018231910A1 (enExample)
ZA (1) ZA202000107B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
KR20220103744A (ko) * 2019-11-14 2022-07-22 에이2에이 파마수티칼스, 잉크. 항암제로서 tacc3을 표적으로 하는 이속사졸 유도체
JP7691991B2 (ja) * 2020-03-06 2025-06-12 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
US11299489B1 (en) 2020-11-19 2022-04-12 National Health Research Institutes Thiazole compounds as protein kinase inhibitors
KR20240005751A (ko) * 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
CA3246244A1 (en) 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. CANCER COMPOSITIONS AND TREATMENT METHODS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
GB0610909D0 (en) * 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
WO2008033746A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US9255072B2 (en) * 2011-03-04 2016-02-09 National Health Rsearch Institutes Pyrazole compounds and thiazole compounds as protein kinases inhibitors
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
WO2018106643A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279143A (zh) * 2015-05-11 2017-01-04 天津国际生物医药联合研究院 噻唑杂环类化合物及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Christopher et al., Drug Metabolism and Disposition, vol. 36, No. 7, pp. 1357-1364, 2008. *

Also Published As

Publication number Publication date
RU2019137573A3 (enExample) 2021-07-23
EP3638237B1 (en) 2023-04-19
EP3638237A4 (en) 2021-01-13
BR112019026577A8 (pt) 2023-04-11
US10300061B2 (en) 2019-05-28
CA3064081A1 (en) 2018-12-20
MY201291A (en) 2024-02-15
TWI667236B (zh) 2019-08-01
ES2949616T3 (es) 2023-10-02
JP2020523348A (ja) 2020-08-06
MX2019014845A (es) 2020-08-06
CA3064081C (en) 2023-03-21
KR20200014350A (ko) 2020-02-10
WO2018231910A1 (en) 2018-12-20
MX393992B (es) 2025-03-24
CN110831596A (zh) 2020-02-21
KR102372288B1 (ko) 2022-03-08
EP3638237A1 (en) 2020-04-22
ZA202000107B (en) 2020-12-23
US20180353509A1 (en) 2018-12-13
NZ759327A (en) 2021-08-27
RU2019137573A (ru) 2021-05-24
AU2018284249A1 (en) 2019-12-12
TW201906836A (zh) 2019-02-16
CN110831596B (zh) 2025-01-24
BR112019026577A2 (pt) 2020-06-23
JP6979595B2 (ja) 2021-12-15

Similar Documents

Publication Publication Date Title
US10300061B2 (en) Aminothiazole compounds as protein kinase inhibitors
AU2018222073B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
EP3411035B1 (en) Aminothiazole compounds and use thereof
BR112012010085B1 (pt) composto, quantidade terapeuticamente eficaz de um composto, formulação farmacêutica
AU2014351571A1 (en) 1 -(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer
EP3952865A1 (en) Heterocyclic compounds as kinase inhibitors for therapeutic uses
AU2020307631B9 (en) Casein kinase 1ε inhibitor, pharmaceutical composition and application thereof
KR20140144709A (ko) 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도
WO2018187294A1 (en) Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN117043151A (zh) 嘧啶或吡啶类衍生物及其医药用途
MX2014009524A (es) Derivados de triazolopiridina como un inhibidor de quinasa tirosina.
RU2772645C2 (ru) Аминотиазольные соединения в качестве ингибиторов протеинкиназ
US11299489B1 (en) Thiazole compounds as protein kinase inhibitors
NZ759327B2 (en) Aminothiazole compounds as protein kinase inhibitors
TWI750905B (zh) 噻唑化合物作為蛋白質激酶抑制劑
BR112019026577B1 (pt) Compostos aminotiazol, composição farmacêutica e uso como inibidores de proteína quinase e no tratamento de câncer
CA3153096A1 (en) Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder
AU2022321449B2 (en) Pyrimidine-4,6-diamine derivative, a preparation method therefor, and a pharmaceutical application thereof
HK40017909A (en) Aminothiazole compounds as protein kinase inhibitors
HK40017909B (en) Aminothiazole compounds as protein kinase inhibitors
CA3088801A1 (en) Compounds for treating rac-gtpase mediated disorder
KR20250136774A (ko) 헤테로아릴 유도체 화합물 및 이의 용도

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NATIONAL HEALTH RESEARCH INSTITUTES

Free format text: FORMER APPLICANT(S): SHIH, CHUAN; NATIONAL HEALTH RESEARCH INSTITUTES

FGA Letters patent sealed or granted (standard patent)